SyrSpend® SF is Fagron’s innovative vehicle range for compounding oral liquid dosage forms. Its unique starch-based active suspending technology provides a low viscosity when shaken to ease rehomogenization, and a high viscosity at rest to keep APIs safely suspended. This ensures high dosing accuracy and consistency throughout treatment, as demonstrated in the time-lapse on the right.
The use of starch also means that SyrSpend® SF is virtually chemically inert and therefore compatible with a broad range of APIs. To demonstrate this wide compatibility, Fagron has started to study the physical-chemical stability of more than 100 commonly used active pharmaceutical ingredients (APIs) in SyrSpend® SF. The API concentration for each study has been selected to allow for easy dosing for children and/or adults, based on an extensive review of commonly prescribed concentrations, scientific literature and (inter)national formularies. The results of these studies will be published in a series of international, peer-reviewed, scientific articles.
A new article has recently been published in the high-impact Journal of Pharmaceutical and Biomedical Analysis. This article deals with the stability of the following 10 APIs, from a variety of pharmacological classes, in SyrSpend® SF:
- Amlodipine besylate
- Chloroquine phosphate
- Pyridoxine hydrochloride
- Tetracycline hydrochloride
An overview of all available formulations with SyrSpend® SF can be found in our free online Compounding Matters formulations database.